首页> 外国专利> A radioimmunoconjugate for diagnosis and treatment of cancer or metastasis and development of cancer or cancer metastasis inhibitor using thereof

A radioimmunoconjugate for diagnosis and treatment of cancer or metastasis and development of cancer or cancer metastasis inhibitor using thereof

机译:用于诊断和治疗癌症或转移的放射免疫缀合物以及使用其的癌症或癌症转移抑制剂的开发

摘要

Disclosed are a radio-immunoconjugate for diagnosis and treatment of cancer or metastasis and development of metastasis inhibitory formulations using the same. More particularly, the present invention provides a radio-immunoconjugate as material indicating a metastatic cancer that has antibody marked with any lanthanum radionuclide and/or gamma, beta or alpha ray emitting radioisotopes targeting a vascular endothelial growth factor receptor (VEGFR). Such a radio-immunoconjugate is advantageous in that it maintains structural stability of a protein and immune activity thereof and is effectively adsorbed to the surface of vascular endothelial cells, thereby being useful as a pre-metastatic site detection factor. When the radio-immunoconjugate is administered to an animal model with a cancer, the radio-immunoconjugate is accumulated in cancer tissues, and therefore, is useful for development of radioactive metastasis inhibitory formulations.
机译:公开了用于诊断和治疗癌症或转移的放射免疫缀合物,以及使用其的转移抑制制剂的开发。更具体地,本发明提供了放射免疫缀合物作为指示转移性癌症的材料,其具有标记有靶向血管内皮生长因子受体(VEGFR)的任何镧放射性核素和/或发射γ,β或α射线的放射性同位素的抗体。这种放射免疫缀合物的优点在于,其维持蛋白质的结构稳定性及其免疫活性,并有效地吸附到血管内皮细胞的表面,从而用作转移前部位的检测因子。当将放射免疫缀合物施用于患有癌症的动物模型时,放射免疫缀合物积聚在癌组织中,因此可用于开发放射性转移抑制制剂。

著录项

  • 公开/公告号KR100998569B1

    专利类型

  • 公开/公告日2010-12-07

    原文格式PDF

  • 申请/专利权人

    申请/专利号KR20080029892

  • 申请日2008-03-31

  • 分类号A61K49/16;A61K51/02;A61K51;

  • 国家 KR

  • 入库时间 2022-08-21 17:52:57

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号